Last quarter (Q ), XTL Biopharmaceuticals Ltd. Sponsored ADR's total revenue was $―, a decrease of ― from the same quarter last year. In Q, XTL Biopharmaceuticals Ltd. Sponsored ADR's net income was $―. See XTL Biopharmaceuticals Ltd. Sponsored ADR’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 655.00K	$ 880.00K	$ 1.03M	$ -948.00K	$ -842.00K	$ -793.00K
Operating Income	$ -655.00K	$ -880.00K	$ -1.03M	$ -948.00K	$ -842.00K	$ -793.00K
Net Non Operating Interest Income Expense	$ -2.00K	$ -468.00K	$ 1.47M	$ -2.01M	$ -505.00K	$ 4.01M
Other Income Expense	$ 57.00K	-	-	-	-	$ 2.75M
Pretax Income	$ -600.00K	$ -1.35M	$ 435.00K	$ -2.95M	$ -1.35M	$ 5.97M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -600.00K	$ -1.35M	$ 435.00K	$ -2.95M	$ -1.35M	$ 8.96M
Basic EPS	$ -0.14	-	-	$ -0.01	-	-
Diluted EPS	$ -0.23	-	-	$ -0.01	-	-
Basic Average Shares	$ 16.35M	$ 544.91M	$ 532.00M	$ 514.21M	$ 514.21M	$ 514.21M
Diluted Average Shares	$ 16.43M	$ 544.91M	$ 532.00M	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 655.00K	$ 880.00K	$ 1.03M	$ -948.00K	$ -842.00K	$ -793.00K
Net Income From Continuing And Discontinued Operation	$ -600.00K	$ -1.35M	$ 435.00K	$ -2.95M	$ -1.35M	$ 8.96M
Normalized Income	$ -352.60K	-	-	-	-	-
Interest Expense	$ 11.00K	-	-	-	-	-
EBIT	$ -1.42M	$ -1.35M	$ -1.03M	$ -948.00K	$ -842.00K	$ 1.96M
EBITDA	$ -1.42M	$ -1.35M	$ -1.03M	-	-	-

Currency in USD

XTL Biopharmaceuticals Ltd. Sponsored ADR Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing